Imaging in medullary thyroid cancer

Thyroid Cancer (Second Edition)

Volumn , Issue , 2005, Pages 311-333

  Behr, T M ^a   Becker, W ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049349985     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27845-1_18     Document Type: Chapter

References (38)

1. Ambrosch A, Pfützner A, Ponder BAJ, Beyer J, Luley C, Lehnert H (1995) Multiple endokrine Neoplasie Ty p 2A-Genetisches Screening bei familiärem Tumorsyndrom. Dtsch Med Wochenschr 120:615-619
2. Becker W, Spiegel W, Reiners C, Börner W (1986) Besonderheiten bei der Nachsorge des C-Zell-Karzinons. Nuklearmediziner 9:167-181
3. Becker W, Börner W, Reiners C (1989) Tc-99m-(V)-DMSA: the new sensitive and specific radiopharmaceutical for imaging metastases of medullary thyroid carcinomas? Horm Metab Res Suppl 21:38-42
4. Behr TM, Becker W (1999) Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for diagnostic predictions? Eur J Nucl Med 26:70-71
5. Behr TM, Becker W (1999) Erhöhte Serum-CEA-Spiegel als Erstmanifestation eines me-dullären Schilddrüsenkarzinoms. Dtsch Med Wochenschr 124:303-394
6. Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W (1997) Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 80:2436-2457
7. Behr TM, Gratz S, Markus PM, Hüfner M, Schauer A, Becker H, Becker W (1997) Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical sign of tumor manifestation? Eur J Nucl Med 24:184-191
8. Behr TM, Jenner N, Radetzky S, Béhé M, Gratz S, Yücekent S, Raue F, Becker W (1998) Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin. Eur J Nucl Med 25:424-430
9. Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W (1999) Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5:3124-3138
10. Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, Becker W (1999) Radiolabeled peptides for targeting of cholecystokinin-B/gastrin receptor expressing tumors: from preclinical development to initial clinical results. J Nucl Med 40:1029-1044
11. Behr TM, Béhé M, Angerstein C, Hüfner M, Becker W (2000) Cholecystokinin-B/gastrin-receptor binding peptides for the staging of known and occult metastatic medullary thyroid cancer. Eur J Nucl Med 27:in press
12. Bergholm U, Bergström R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132-138
13. Brunt LM, Wells SA Jr (1987) Advances in the diagnosis and treatment of medullary thyroid carcinoma. Endocr Surg 67:263
14. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Bosetto E (1984) Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278-285
15. Dörr U, Frank-Raue K, Raue F, Buhr HJ, Hehrmann R, Iser G, Bihl H (1993) Localization of recurrences from medullary thyroid carcinoma by somatostatin-receptor-scintigraphy (abstract). Eur J Nucl Med 20:843
16. Dörr U, Würstlin S, Frank-Raue K, Raue F, Hehrmann R, Iser G, Scholz M, Guhl L, Buhr HJ, Bihl H (1993) Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. In: Bihl H, Dörr U (eds) So-matostatin receptor imaging. (Hormone and Metabolic Research Suppl. vol 27). Thieme, Stuttgart New York, pp 48-55
17. Hazard JB, Hawk WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid: a clini-copathological entity. J Clin Endocrinol Metab 19:152
18. Hilditch TE, Connell JMC, Elliott AT, Murray T, Reed NS (1986) Poor results with tech-netium-99m (V) DMSA and iodine-131 MIBG in the imaging of medullary thyroid carcinoma. J Nucl Med 27:1150-1153
19. Jensen RT (1999) Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 10:156-172
20. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 55:5946-5951
21. 131I-labeled anti-CEA antibodies. J Nucl Med 37:875-881
22. Juweid ME, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn RM, Siegel J, Kamal T, Goldenberg DM (1996) Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 14:1209-1217
23. Kameda Y, Ikeda K, Ikeda A (1981) Uptake of radioiodine in follicles of dog C-cell complexes studied by autoradiograph and immunoperoxidase staining. Anat Rec 200:461-470
24. 18F-FDG-PET, MRT und CT in der Nachsorge des medullären Schilddrüsenkarzinoms. Nucl Med 35: A60
25. Mendelsohn G, Wells Jr SA, Baylin SB (1984) Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. Cancer 54:657-662
26. Nusynowitz ML, Pollard E, Benedetto AR, Lecklitner ML, Ware RW (1982) Treatment of medullary carcinoma of the thyroid with I-131. J Nucl Med 23:143-146
27. O'Riordain DS, O'Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA (1994) Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017
28. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A (1991) Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol 95:300-308
29. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78:826-829
30. 111In-labelled monoclonal anti-CEA antibody fragment. Nucl Med 25:227-231
31. Reubi JC, Waser B (1996) Unexpected high incidence of cholecystokinin/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 67:644-647
32. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E (1991) Somatosta-tin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567-573
33. Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 57:1377-1386
34. Samaan NA, Schultz PN, Hickey RC (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801-808
35. Smith JP, Stock EA, Wotring MG, McLaughlin PJ, Zagon IS (1996) Characterization of the CCK-B/gastrin-like receptor in human colon cancer. Am J Physiol 271:R797-R805
36. Vierbuchen M, Schröder S, Larena A, Uhlenbruck G, Fischer R (1994) Native and sialic acid masked Lewis(a) antigen reactivity in medullary thyroid carcinoma. Distinct tumour-associated and prognostic relevant antigens. Virchows Arch 424:205-211
37. Wells SA Jr, Baylin SB, Linehan WM, et al. (1978) Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188:139.
38. Williams ED (1966) Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 19:114